Quotient and Ipsen increase their partnership to deal with ultra-rare ailments
Quotient Sciences has expanded its industrial collaboration with Ipsen, specializing in the manufacturing of Sohonos (Palovarotene) for fibrodysplasia ossificans progressiva (FOP).
FOP is a particularly uncommon situation, affecting fewer than 1,000 individuals worldwide.
Uncover B2B advertising that delivers
Mix enterprise intelligence and editorial excellence to achieve engaged professionals throughout 36 main media platforms.
Extra info
The collaboration contains the containment, specialised remedy and sustainable provide of this extremely potent molecule.
The settlement contains Ipsen’s funding in further tools at Quotient Sciences’ facility in Boothwyn, Pennsylvania, USA.
This features a pneumatic closed switch system, which maintains combine integrity throughout secure materials switch, and a versatile metering isolator designed to enhance operator security and remove the necessity for specialised cleansing procedures.
Quotient Sciences has now expanded its capabilities to course of extremely potent lively pharmaceutical substances (HPAPI) and merchandise with occupational publicity limits (OELs) of 1 µg/m³ or much less.
The brand new additions additionally allow seamless integration with present tools, simplifying the manufacturing course of for complicated drug molecules.
The expanded partnership goals to make sure a dependable industrial provide of FOP remedy whereas increasing capability to deal with a number of extremely potent compounds on a industrial scale.
This helps the necessity for versatile options within the remedy of uncommon ailments the place affected person populations are small and product volumes are restricted.
Ipsen chosen Quotient Sciences due to its established operational capabilities and in depth expertise in managing world shipments. The corporate shall be chargeable for guaranteeing the secure and well timed supply of the remedy to worldwide markets.
Marlene Leuenberger, vice chairman and basic supervisor of Quotient Sciences Philadelphia mentioned, “This important funding in superior containment and manufacturing expertise at our Boothwyn facility underscores Quotient Sciences’ continued dedication to supporting sufferers with ultra-rare ailments.
“By increasing our capabilities in dealing with extremely potent compounds, we’re not solely guaranteeing dependable provide of crucial therapies like Sohonos (Palovarotene) for the FOP neighborhood, but additionally strengthening our dedication to delivering versatile, high-quality options for our companions with specialised wants, particularly for extremely potent compounds.”
In September 2025, Quotient Sciences partnered with the UK Middle for Course of Innovation (CPI) to speed up the creation of ribonucleic acid (RNA)-based therapies.
